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Homocysteine (Hcy) is a sulfur-containing amino acid
and not present in our diet. It is synthesized as an
intermediate product during transulfuration of cysteine
from methionine requiring cystathionine β synthase
(CBS) and a cofactor-vitamin B6. It can be remethylated
to methionine by the enzyme methylene tetrahydrofolate
reductase (MTHFR) with vitamin B12 and folic acid as
cofactors. Hcy is normally present in plasma in a
concentration of 5-15 µmol/L with 75% being protein
bound. Mildly high levels may be seen in 5-7% of
general population.1 Hyperhomocysteinemia (HHcy)
may be moderate, intermediate and severe referring to
plasma Hcy levels of 16-30, 31-100 or >100 µmol/L,
respectively; and may be inherited or acquired. Genetic
defects with mutations of MHTFR enzymes result in
intermediate (50-100 umol/L), while CBS deficiency will
lead to severe hyperhomocysteinemia (>100 µmol/L).2
Besides being inherited, HHcy may be the consequence
of smoking, nutritional deficiencies (of vitamin B6, B12
and folic acid), intake of anti-cholesterol agents, renal
failure and thyroid disorders.
Hcy has been identified as an independent risk factor for
venous thrombosis; besides, its association with
vascular events like myocardial infarction and stroke. Its
role in osteoporosis, macular degeneration, adverse
pregnancy outcome and dementia is supported in some
but not all studies. A number of reports described
thrombosis in unusual sites such as retinal vein as a
consequence of high Hcy levels. Heijer et al. in 1996
studied 269 patients with first episode of deep venous
thrombosis with an equal number of matched controls;
and observed high homocysteine levels in 13% cases as
compared to 10% controls with an odd ratio of 2.5 (95%
confidence interval; 1.2 - 5.2).3 The study demonstrated
that the risk of thrombosis was significant at Hcy level
above 22 µmol/L at a mean age of 44 years (range 16-
70). This study is important as it was the first to show the
risk of thrombosis with moderate homocysteinemia.
The relationship between Hcy and thrombosis is
complex and multifactorial. Blood vessels (vascular
injury and endothelial dysfunction), platelets (increased
platelet activity), and coagulation factors (increased
tissue factor expression, increased factor V activity,
amplified thrombin generation, reduced anticoagulants
and fibrinolysis)3 are all affected by high levels of
homocysteine. Molecular mechanisms are poorly
understood and involve oxidative stress, DNA hypo-
methylation, and pro-inflammatory effects.3 It is also
suggested that homocysteine may not cause thrombosis
by itself but does so in the presence of other factors
such as methionine.
Should Hcy be measured? Current understanding is that
Hcy should not be measured in non-selected general
population. However, there is a substantial evidence that
homocysteine levels may be checked in young patients
who present with unexplained thromboembolic disease.
Lussana et al. studied 19,678 patients with thrombosis
who had thrombophilia screening over 12 years in six
Italian thrombosis centers. Median level of homo-
cysteine was 130 µmol/L (range 101-262) in patients
with a median age of 47 years (range 19-83). Venous
thromboembolism (71%) was seen more frequently than
arterial thromboembolism (26%), while recurrent
thrombosis was seen in 42% patients.4 Similarly, a meta-
analysis of 23 cohort and 33 case-control studies
demonstrated significant association between cerebral
venous thrombosis and inherited thrombophilia and
hyperhomocysteinemia.5 In Denmark, a cohort of
patients (n=184) with hyperhomocysteinemia was
studied from 1996 to 2011. A MTHFR c.677TT genotype
was identified in 49%, while CBS c.833T>C (p.I278T) in
4% patients. It was remarkable that patients having a
CBS mutation had thrombosis at a young age of 25
years, approximately. The authors concluded that Hcy
should be part of the thrombophilia screening for
unexplainable arterial or venous thrombosis in
individuals below 40 years.2
Since high Hcy levels may result from vitamin B or
nutritional deficiencies, it is reasonable to argue if
vitamin B supplementation will lower the risk of
thromboembolism. Several randomized homocysteine-
lowering therapy trials failed to show that vitamin B
supplementation substantially modifies the risk of
thrombosis or prevents its recurrence despite lowering
Hcy levels. Interestingly, B-vitamins and betaine therapy
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may be beneficial in reducing the thrombosis risk in
patients with homocystinuria, a metabolic syndrome that
is characterized by severe hyper-homocysteinemia, and
was first described in 1962. Since thrombosis may be
the first clinical manifestation of homocystinuria in
patients that may be silent otherwise, evidence suggests
that Hcy measurement may be helpful for identifying
subjects at a greater risk of disease. Such patients may
benefit from a more aggressive management of other
modifiable risk factors, as recently demonstrated by
result of the 5-year Fenofibrate Intervention and Event
Lowering in Diabetes (FIELD) trial.6
The current literature suggests that homocysteine is a
biomarker for thrombosis but is not involved in the
etiology of thrombosis by itself. There are other cryptic
key players that act in synergy with homocysteine to
potentiate thrombosis. In a local study in 2006, mild
hyperhomocysteinemia (15-25 µmol/L) was frequent in
patients with acute myocardial infarction. Though, this
study failed to establish any association of hyper-
homocysteinemia and MHTFR 677C>T mutation with
coronary artery disease, the synergistic effect of other
risk factors with hyperhomocysteinemia could not be
ruled out.7
Mean plasma homocysteine levels in Pakistani normal
adults were reported high at 16.4±4.9 µmol/L,7 while still
higher levels were reported in young patients with
coronary artery disease (mean levels 18.1±5.3
mmol/L).8 Secondly, poor dietary habits with absent meat
intake can further aggravate hyperhomocysteinemia,
making them vulnerable to cardiac disease.9 In addition
to nutritional deficiencies, Mohsin et al. reported that
individuals having MTHFR 677CT or TT genotypes were
at greater risk of developing hyperhomocysteinemia.10
All these findings indicate that Pakistanis are more
prone to homocysteinemia. It is amazing that simple folic
acid fortification (140 µg/100g) of the US grain supply by
the Food and Drug Administration (FDA) in 1996 is
expected to have decreased the US populations' plasma
homocysteine levels by 53%. With a human develop-
ment index of 0.538, Pakistan ranks 147th of 188
countries. Poverty, lack of education, and dearth of
health provisions are the major barriers to proper
nutrition. High homocysteine levels in our population
mandate the need for mass micronutrient supple-
mentation for preventing coronary artery disease and
other thrombotic events.
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